度鲁特韦钠盐
- CAS编号: 1051375-19-9
- 分子式: C20H18F2N3NaO5
- 分子量: 441.36
- PubChem编号: 46216142
库存信息
库存信息
库存信息
库存信息
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
D275163-5mg | 5mg | 现货 | | |
D275163-25mg | 25mg | 现货 | | |
D275163-50mg | 50mg | 现货 | | |
D275163-100mg | 100mg | 现货 | |
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
D275163-5mg | 5mg | 现货 | | |
D275163-25mg | 25mg | 现货 | | |
D275163-50mg | 50mg | 现货 | | |
D275163-100mg | 100mg | 现货 | |
规格或纯度 | 99% |
---|---|
英文名称 | Dolutegravir Sodium |
别名 | (4R,12aS)-9-[(2,4-二氟苯基)甲基氨基甲酰基]-4-甲基-6,8-二氧代-3,4,12,12a-四氢-2H-吡啶基[5,6]吡嗪并[2,6-b][1,3]恶嗪-7-油酸钠盐 |
英文别名 | (4R,12aS)-9-[(2,4-Difluorophenyl)methylcarbamoyl]-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[5,6]pyrazino[2,6-b][1,3]oxazin-7-olatesodiumsalt |
生化机理 | Dolutegravir Sodium是一种HIV-1整合酶抑制剂,IC 50为2.7nM。对感染细胞中的总病毒DNA合成没有影响,但会阻止病毒DNA整合到宿主DNA中。 |
储存温度 | -20°C储存 |
运输条件 | 超低温冰袋运输 |
产品介绍 |
Integrase inhibitors are a new class of antiretroviral drugs blocking the action of HIV integrase, which catalyses several key steps in the life cycle of the virus and is essential for insertion of the viral genome into the host cell DNA. GSK1349572 is a next-generation HIV integrase (IN) inhibitor. In vitro: GSK1349572 is a two-metal-binding HIV integrase strand transfer inhibitor whose mechanism of action was established through resistance passage experiments, integrase enzyme assays, mechanistic cellular assays and activity against viral strains resistant to other classes of anti-HIV agents. In a variety of cellular antiviral assays, GSK1349572 inhibited HIV replication with subnanomolar or low-nanomolar potency and with a selectivity index of 9,400. The protein-adjusted half-maximal effective concentration extrapolated to 100% human serum was 38 nM . In vivo: No animial in vivo data are available for GSK1349572 so far. Clinical trial: GSK1349572 was effective when given once daily without a pharmacokinetic booster and was well tolerated at all assessed doses. These findings support the assessment of once daily 50 mg GSK1349572 in phase 3 trials. |
IUPAC Name | sodium;(3S,7R)-13-[(2,4-difluorophenyl)methylcarbamoyl]-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-dien-11-olate |
---|---|
INCHI | InChI=1S/C20H19F2N3O5.Na/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22;/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28);/q;+1/p-1/t10-,15+;/m1./s1 |
InChi Key | UGWJRRXTMKRYNK-VSLILLSYSA-M |
Canonical SMILES | CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)[O-].[Na+] |
分子式 |
C20H18F2N3NaO5 |
PubChem CID | 46216142 |
分子量 | 441.36 |
溶解性 | 0.2mg/ml in DMSO. |
---|---|
敏感性 | 对湿度敏感 |
象形图 |
Environmental Hazard |
---|---|
信号词 | Warning |
危险声明 |
H400: Very toxic to aquatic life H410: Very toxic to aquatic life with long lasting effects |
预防措施声明 | P273,P501,P391 |